ADC-33 in complex with boronic acid transition state inhibitor MB076

1-[(2R)-2-{2-[(5-amino-1,3,4-thiadiazol-2-yl)sulfanyl]acetamido}-2-boronoethyl]-1H-1,2,3-triazole-4-carboxylic acid

Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits Acinetobacter-Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum

ADC-33 (3.5 mg/mL) in 25% w/v polyethylene glycol (PEG) 1500, 0.1 M succinate/ phosphate/ glycine

National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

BATSI, inhibitor, Acinetobacter-derived Cephalosporinase, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR complex